# A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

> **NCT02912949** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Partner Therapeutics, Inc.** · enrollment: 250 (estimated)

## Conditions studied

- Solid Tumours Harboring NRG1 Fusion
- NSCLC Harboring NRG1 Fusion
- Pancreatic Cancer Harboring NRG1 Fusion
- NRG1 Fusion

## Interventions

- **DRUG:** zenocutuzumab (MCLA-128)

## Key facts

- **NCT ID:** NCT02912949
- **Lead sponsor:** Partner Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02912949

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02912949, "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02912949. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*